tgf-β2 antisense oligonucleotide
Nucleic acidexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02406833)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Transforming growth factor beta-2ANTISENSE INHIBITOR
TGFB2 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- tgf-beta2 antisense oligonucleotide
- tgf-β2 antisense oligonucleotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02406833 | Phase 1 | Apr 1, 2015 | Isarna Therapeutics GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Isarna Therapeutics GmbH | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1